CytoCore purchases contract for 10% undiluted interest in Diamics

By Lisa Kerner

Erie, Pa., Feb. 24 - CytoCore, Inc. said it agreed to buy a contract from a private individual for the right to receive a 10% undiluted interest in Diamics, Inc., a privately held California company founded by Peter Gombrich, former chief executive officer and chairman of Molecular Diagnostics (now CytoCore).

CytoCore intends to pursue its ownership rights in Diamics, according to a company news release.

Chicago-based CytoCore develops cancer screening systems used in laboratories or at the point-of-care to assist in the early detection of cervical, endometrial and other cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.